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David H. Vesole,1 Lijun Zhang,2 Neal Flomenberg,3 Philip R. Greipp,4 Hillard M. Lazarus5 for
the ECOG Myeloma and BMT CommitteesConventional allogeneic hematopoietic stem cell transplantation (HSCT) for multiple myeloma is associated
with high transplantation-related mortality (TRM). Nonmyeloablative allogeneic transplantation (NST) uses
the well-known graft-versus-myeloma (GVM) effect to eradicate minimal residual disease. The Eastern Co-
operative Oncology Group conducted a Phase II trial of autologous HSCT followed by NST to provide max-
imal tumor cytoreduction to allow for a subsequent GVM effect. Patients receivedmelphalan 200mg/m2 with
autologous HSCT, followed by fludarabine 30 mg/m2 in 5 daily doses and cyclophosphamide 1 g/m2 in 2 daily
doses with matched sibling donor NST. Graft-versus-host disease (GVHD) prophylaxis included cyclospor-
ine and corticosteroids. The primary endpoints were TRM, graft failure, acute GVHD, progression-free sur-
vival (PFS), and overall survival (OS). Thirty-two patients were enrolled into the study; 23 patients completed
both transplantations (72%). Best responses post-NSTwere 7 (30%) complete remission (CR), 11 (48%) par-
tial remission (PR), 2 (9%) no response, and 3 (13%) not evaluable. Acute grade III-IVGVHDwas observed in
4 patients (17%), and chronic GVHD was seen in 13 patients (57%; 7 limited, 6 extensive). Chronic GVHD
resulted in the following responses: 3 (23%) CR, 1 continuing CR, and 6 (46%) PR. Two patients (8.7%) had
early TRM. With a median follow up of 4.6 years, the median PFS was 3.6 years, and the 2-year OS was 78%.
Our findings indicate that autologous HSCT followed by NST is feasible, with a low early TRM in a cooper-
ative group setting. The overall response rate was 78%, including 30% CR, similar to other reports for
autologous HSCT-NST. Because a plateau in PFS or OS was not observed with this treatment approach
even in patients achieving CR, we suggest that future studies use posttransplantation maintenance therapy.
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Conventional allogeneic hematopoietic stem cell
transplantation (HSCT) in patients with multiple
myeloma (MM) is associated with a transplantation-
related mortality (TRM) between 20% and 60%
[1-3]. Recent improvements in supportive care and
patient selection have dropped TRM to the 20% range
[4]. Subsequently, efforts to further reduce the trans-
plantation-related morbidity and TRM have resulted
in less toxic nonmyeloablative allogeneic transplanta-
tion (NST) regimens. Furthermore, earlier studies
demonstrated that donor lymphocyte infusion (DLI)
produced a graft-versus-myeloma (GVM) effect in pa-
tients with persistent/relapsed disease after allogeneic
HSCT. This led to the development of ECOG
E1A97, using DLI for relapsed/persistent myeloma83
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tempted to eradicate residual disease by harnessing
the known GVM effect through infusions of alloreac-
tive donor T lymphocytes infused in the donor graft.
Preliminary studies of NST in relapsed and/or refrac-
tory MM demonstrated significant complete remission
(CR) and low 100-day post-NST TRM. Although re-
sponse rates were high, the vast majority of patients
with extensive disease at the time of transplantation
relapsed within the first year [5-8]. Ultimately, overall
TRM was not significantly reduced, just deferred to
a later time, with TRM exceeding 30% at 2 years
posttransplantation in some reports [5]. Furthermore,
very few patients achieved long-term disease control.
Subsequent approaches investigated tandem trans-
plantations earlier in the disease course, involving
high-dose therapy with autologous HSCT to provide
maximal tumor cytoreduction, followed by NST to
eradicate minimal residual disease through the GVM
effect [9-15]. We report the combined results of
ECOG E4A98, a Phase II trial of autologous HSCT
for maximal tumor cytoreduction, followed by
a matched sibling NST to allow for a GVM effect.
In addition, we present the results of a parallel DLI
trial (E1A97).METHODS
Eligibility Criteria
Patients age 18 to 70 years with previously treated
symptomatic MM were eligible for enrollment on the
study. Patients were eligible as consolidation after con-
ventional induction chemotherapy or as part of salvage
therapy. There was no restriction of previous lines of
therapy except previous autologous or allogeneic
HSCT. Chemotherapy sensitivity was not required
for study entry. Patients must have had an adequate
performance status (ECOG 0-2), acceptable physio-
logical organ function, and an HLA-A, -B, and -DR
genotypically identical sibling donor. Written in-
formed consent was obtained on enrollment, and the
study design was approved by the institutional review
boards of all participating institutions.
High-Dose Melphalan/Autologous HSCT
Peripheral blood stem cells were collected accord-
ing to institutional guidelines. A total of 32 patients,
with a previously collected minimum of 2  106
CD341 cells/kg, were enrolled and received high-
dose melphalan 200 mg/m2 i.v. in a single dose over 5
to 15 minutes within 30 minutes of reconstitution on
day -1. Peripheral stem cell reinfusion was performed
on day 0. On day11 postinfusion, granulocytes macro-
phage colony-stimulating factor (GM-CSF) 250mg/m2
was administered daily until the neutrophil count
exceeded 1000/mm3 for 3 consecutive days. Patientsreceived prophylaxis against herpes simplex virus, var-
icella zoster, Pneumocystis carini, and Candida according
to institutional protocol.Nonmyeloablative Allogeneic HSCT
Eligibility
Once the eligibility of the patient and donor were
reconfirmed, the patient underwent NST between
100 to 182 days after autologous HSCT. Patients
were eligible to proceed to allogeneic HSCT regard-
less of disease status after autologous HSCT; however,
patients with progressive disease could not receive
cytotoxic chemotherapy between transplantations.
Allogeneic Stem Cell Mobilization
Allogeneic peripheral stem cells were collected us-
ing G-CSF priming, typically at a dose of 10 mg/kg/day
beginning 2 to 5 days before collection according to
institutional protocol. The target cell dose was a mini-
mum of 5  106 CD341 cells/kg (recipient weight)
through 1 or 2 aphereses. The use of fresh stem cells
was recommended whenever possible, although the
protocol did allow for cryopreservation if necessary.
Conditioning Regimen/Stem Cell Infusion
Conditioning included fludarabine at a dose of 30
mg/m2 (150 mg/m2 total dose) i.v. per day for each
of 5 consecutive days beginning day -6. Fludarabine
was reduced to 20 mg/m2 if renal function was im-
paired (creatinine, 1.6 to 2 mg/dL) or if the patient
was age . 60 years. Cyclophosphamide 1 g/m2/day
i.v. (2 g/m2 total dose) was administered for 2 consec-
utive days starting on day -3. Allogeneic stem cells
were infused on day 0 and, if necessary, on day 11.
Starting on day 11, patients received GM-CSF 250
mg/m2/day until the neutrophil count was . 1000/
mm3 for 3 consecutive days.
Posttransplantation Immunosuppression
CSA was administered starting on day -1 at a dose
of 3.0 mg/kg/day i.v., given in 2 divided doses (1.5 mg/
kg) every 12 hours. Patients could be converted to oral
CSA per institutional guidelines. Unless toxicity or
GVHD occurred, CSA was continued at the same
dose until day 160. After day 160, the dose was
reduced by 10% to 20% every 1 to 2 weeks, with
the drug discontinued approximately 4 months after
allografting.
Beginning on day13, methylprednisolone (or oral
prednisone equivalent) was administered at a dose of 1
mg/kg/day for 2 weeks. Thereafter, in the absence of
GVHD, the dose was reduced to approximately 0.6
mg/kg after 2 weeks, 0.3 mg/kg after another 2 weeks,
and 0.15 mg/kg after another 2 weeks. The final taper
was done in accordance with institutional guidelines. If
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according to institutional protocol. If in addition
the patient met the criteria for grade II-IV GVHD,
then 5 doses of daclizumab (Zenapax, Roche Pharma-
ceuticals, Nutley, NJ), 1 mg/kg every 3 days, were
administered.
All patients received prophylaxis against herpes
simplex virus, varicella zoster, Pneumocystis carini, and
Candida according to institutional guidelines for at
least the first 100 days posttransplantation.
Donor Lymphocyte Infusion
Patients with persistent disease or recurrent dis-
ease 6 months after undergoing HLA-identical sibling
allogeneic HSCT were eligible to participate in an
ECOG Phase II clinical trial (E1A97) using DLI.
The objective of this ancillary study was to assess re-
sponse, safety, and toxicity. Eligible patients must
have discontinued any immunosuppressive therapy ex-
cept prednisone (no more than 0.25 mg/kg/day) for
previous GVHD for at least 4 weeks before receiving
DLI. Patients could have received salvage chemother-
apy before DLI, but at least 4 weeks previously. Donor
lymphocytes for infusion were collected in the steady
state from the original sibling donor and administered
at an initial dose of 5  107 CD31 cells/kg of ideal
body weight; however, patients with rapidly progres-
sive disease could receive a dose of 1.5  108 CD31
cells/kg. Patients who did not achieve a complete re-
sponse could receive up to 2 additional escalating doses
of DLI, and patients with evidence of progressive dis-
ease at 8 weeks or with stable disease or partial re-
sponse (PR) at 12 weeks could be retreated. The
intended second dose level was 1.5  108 CD31
cells/kg, and the third dose level was 4.5  108
CD31 cells/kg.
Response/Engraftment Criteria
Responses were evaluated monthly for the first
year after autologous HSCT and every 2 months
thereafter, based on the EBMT/IBMTR criteria of
Blade et al. [16]. The date of neutrophil engraftment
was defined as the first day of 3 consecutive days on
which the absolute neutrophil count exceeded 500/
mm3. The date of platelet engraftment was defined
as the first of 3 consecutive measurements with a plate-
let count exceeding 20,000/mm3 (without platelet
transfusions).Study Design
The primary goal of this Phase II study was to eval-
uate the early incidence rate of mortality at day 100 af-
ter NST. By design, the study was suspended after the
first 19 patients were treated. Because no patient died
within the first 100 days after mini-allogeneic trans-
plantation, the study was reopened. Additional objec-tives were early graft failure (within the first 100
days), incidence of grade III-IV acute GVHD, toxic-
ities, progression-free survival (PFS), and overall sur-
vival (OS). The study was closed early in January
2005 because of slow patient accrual.Statistical Methods
Cumulative incidence estimates were calculated
for acute and chronic GVHD. OS and PFS were esti-
mated using the method of Kaplan and Meier [17] on
the 23 patients who had undergone both transplanta-
tions. In the PFS analysis, patients were counted as
events if they progressed or died due to any cause,
and if death without documented progression oc-
curred within 3 months of the last disease evaluation.
The PFS time was calculated as the time from the reg-
istration date of autologous HSCT to the time of pro-
gression or death, whichever occurred first. The effect
of chronic GVHD on PFS and OS was investigated us-
ing a Cox proportional hazards model, with chronic
GVHD status included as a time-dependent variable.
Follow-up was as of May 2008.RESULTS
Patient Characteristics
A total of 32 patients from 10 institutions were en-
rolled into the study between May 2001 and January
2005. All 32 patients were eligible and were included
in the analysis, although only 23 received both trans-
plantations. The patient characteristics are summa-
rized in Table 1. The median patient age was 52
years, and the median time from diagnosis to first au-
tologous HSCT was 7.7 months. Using the ECOG
response criteria, 70% of the patients had chemother-
apy-sensitive disease at the time of autologous HSCT,
including 13% CR (serum and urine immunofixation
electrophoresis–negative, bone marrow containing\
3% plasma cells) and 57% PR; 10% had progressive
disease. The median beta-2 microglobulin value was
2.6 mg/dL.Planned Autologous HSCT
Mobilization and collection of peripheral blood
stem cells were done according to institutional proto-
col. All 32 patients enrolled underwent autologous
HSCT. The median time to neutrophil engraftment
was 13 days, and the median time to platelet engraft-
ment was 11 days. No autologous HSCT-related
deaths occurred; 13 grade III and 12 grade IV nonhe-
matologic toxicities were reported. The best responses
to autologous HSCT were 1 near CR (nCR), 3 contin-
ued CR (CCR), 17 PR, 6 no response (NR), and 5 not
evaluable (NE) (Table 2).
Table 1. Patient Characteristics at Autologous HSCT Baseline
Variable
Patients with
Autografts (n 5 32)
Patients with Both
Transplants (n 5 23)
Age, years, median (range) 52 (32 to 68) 51 (32 to 64)
Sex, male/female 19 (59%)/13(41%) 14 (61%)/9(39%)
Previous regimens, median (range) NA* NA
Median time from diagnosis to autograft, days,
median (range)
228 (110 to 1037) 223 (110 to 1037)
Beta-2 microglobulin, mg/dL, median (range) 2.6 (0.9 to 18.3) 2.6 (0.9 to 5.8)
LDH, U/L, median (range) 226 (136 to 1156) 228 (136 to 1156)
Durie-Salmon stage at initial diagnosis 3(9%)/7(22%)/22(69%) 2(9%)/6(26%)/15(65%)
Serum M spike, g/dL, median (range) 0.6 (0 to 5.2) 0.6 (0 to 3.4)
Serum heavy chain, n (%)
G 15 (75) 12 (75)
A 5 (25) 4 (25)
Unknown 12 7
Serum light chain, n (%)
Kappa 12 (48) 9 (47)
Lambda 13 (52) 10 (52)
Unknown 7 4
Disease status before transplantation, n (%)
CR 4 (13.3) 2(9.1)
PR 17 (56.7) 15(68.2)
SD 4 (13.3) 3(13.6)
PD 3 (10) 2(9.1)
Other 2 (6.7) 0( 0)
Unknown 2 1
NA, not available.
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A total of 23 patients continued onto the mini-
allogeneic transplantation; the dropout rate after auto-
grafting was 28%. The median time from autologous
HSCT to NST was 124 days. When the trial was being
designed, a delay of 100 to 182 days was considered
necessary to allow sufficient time for the patient to re-
cover from the first transplantation. Reasons for dis-
continuing the protocol therapy included patient
withdrawal/refusal (n 5 2), toxicities (n 5 2; multiple
medical problems in 1 patient; intractable pain syn-
drome in the other), symptomatic deterioration with-
out progression (n 5 1), other complicating disease
(n5 1), and death (nondisease related; n5 1). The me-
dian time to neutrophil engraftment was 11 days, andTable 2. Best Response
n (%)
Best overall response (autograft +
mini-allograft) (n 5 23)
CR* 7 (30%)
PR 11 (48%)
NR 2 (9%)
Unevaluable† 3 (13%)
Best response to autograft (n 5 32)
CCR 3 (9%)
nCR 1 (3%)
PR 17 (53%)
NR 6 (19%)
Unevaluable‡ 5 (16%)
*Including 2 CCR.
†Patient noncompliance (n 5 1), absence of appropriate laboratory
assessment (n 5 2).
‡Patient noncompliance (n5 1), insurance issue (n5 1), no disease as-
sessment (n5 1), absence of appropriate laboratory assessment (n5 2).the median time to platelet engraftment was 0 days
There were 9 grade III and 11 grade IV nonhemato-
logic toxicities were reported. One patient who
achieved PR experienced graft failure after initial en-
graftment and subsequently died.
Graft-versus-Host Disease
The cumulative incidence of GVHD after NST
was acute GVHD (median 23 days), 70% grade I-IV
and 17% grade III-IV, and chronic GVHD (median
169 days), 57% overall (6 extensive and 7 limited).
(Figure 1). Chronic GVHD resulted in 3 CR (23%),
1 CCR, and 6 PR (46%) (Table 3). With a median fol-
low-up of 4.3 years after NST, 4 of the 13 patients with
chronic GVHD (31%) were in remission, 6 had pro-
gressed (46%), and 3 had died (23%).
Donor Lymphocyte Infusion
Seven patients were enrolled on the ancillary
E1A97 Phase II trial before closure for poor accrual;
only 5 were deemed eligible. Only 1 patient received
a second DLI treatment. Of the 5 eligible patients, 3
were dropped because of toxicities, including grade
IV or higher toxicity in 2 patients (cardiac, multisystem
failure grade III GVHD), 1 of whom had progressive
disease and the other completed treatment. No patient
developed marrow hypoplasia or aplasia. DLI re-
sponses included progressive disease in 1 patient and
stable disease in 4 patients, only one of whom subse-
quently progressed. Two patients had acute GVHD
(1 with grade III), and 4 patients had chronic GVHD
(3 limited and 1 extensive). The median PFS was 5
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Figure 1. Cumulative incidence of acute and chronic GVHD.
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ing the results of E4A98 and E1A97, 19 patients devel-
oped acute GVHD and 17 patients developed chronic
GVHD, with an overall response of 5 CR (including 1
CCR in E4A98 and 1 CR from an ineligible patient en-
rolled in E1A97), 6 PR, 5 NR, and 1 progressive dis-
ease. The median duration of response was 42.4
months. Of the 17 patients with chronic GVHD, 7
had progressed at the time of this analysis.Disease Response
Table 2 summarizes the response to autografting
and to autografting followed by NST. Of the 32 pa-
tients completing at least autografting, 21 (65%)
achieved PR or CR after the autologous HSCT. For
the 23 patients completing both transplantations, the
overall response rate was 78%. At a median follow-
up of 4.6 years from enrollment for autografting
(range, 0.4 to 5.7 years), the best overall responseTable 3. Disease Response to Chronic GVHD
Case
Chronic
GVHD
Best Response
to Autograft
Best Overall
Response (Autograft +
Mini-Allograft)
Days Since
Allograft
40002 Extensive PR PR 123
40006 Extensive PR PR 200
40008 Limited NC NR 140
40011 Extensive nCR CR 396
40012 Limited NR NR 463
40014 Extensive NR CR 134
40015 Extensive NR PR 137
40017 Limited NR NR 169
40019 Limited NR PR 642
40022 Limited CCR CCR 124
40024 Limited PR PR 466
40025 Extensive PR PR 177
40026 Limited NR CR 104rate included 7 (30%) CR (2 in CCR), 11 (48%) PR,
2 (9%) NR, and 3 (13%) NE. Only 1 relapse occurred
among the 7 patients achieving CR, whereas 8 of 11
patients in PR relapsed, with a median time to relapse
of 2.8 years.Nonrelapse Mortality and Survival
With a median follow up of 4.6 years from registra-
tion, the 23 patients who completed both transplanta-
tions had a median PFS of 3.6 years and a 2-year
survival rate of 78% (95% confidence interval [CI] 5
61% to 95%), and all 32 enrolled patients had a median
PFS of 4.4 years and a 2-year survival rate of 78% (95%
CI 5 62% to 90%) (Figure 2). No TRM occurred
within the first 100 days in the first 19 patients; 2 of
the subsequent 13 patients (8.7%; 95% CI 5 1.6%
to 24.9%) experienced TRM, 1 patient from GVHD
on day141 and the other from pneumonia/aspergillus
on day 174. As of February 2008, 9 patients had died,
3 transplantation-related (GVHD) and 6 non–trans-
plantation-related, including progressive disease (n 5
2), sepsis (n 5 2), and thrombotic vascular events (n
5 2) ranging from 11 months to 4.5 years posttrans-
plantation. Chronic GVHD did not improve PFS or
OS (P 5 .16 and .30, respectively).Univariate and Multivariate Analyses
Univariate analysis of prognostic variables in-
cluded age, sex, beta-2 microglobulin level, lactate
dehydrogenase (LDH) level, creatinine level, Durie-
Salmon stage, GVHD status, and chemotherapy sensi-
tivity. Median OS was significantly shorter in patients
with higher LDH values (P 5 .048, hazard ratio 5
1.003; 95% CI 5 1.000 to 1.005). No other variable
had prognostic significance in this small study. In the
multivariate analysis using a Cox proportional hazards
model [18] with all of the possible prognostic variables
included, no variable was significantly associated with
PFS or OS.Years
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Figure 2. OS and PFS for patients undergoing tandem transplantation.
Three unevaluable patients are excluded from PFS.
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In this study, we investigated the feasibility and
outcome of an autologous-nonmyeloablative alloge-
neic tandem HSCT strategy within the ECOG. At
the time of study design in 1998, there were no re-
ported single or multi-institutional clinical trials in-
corporating this novel approach of autologous
HSCT for maximum cytoreduction followed by allo-
geneic NST to allow for a GVM. One of the primary
endpoints of the study was early mortality. This was
the basis for the 2-stage design, with a planned stop-
ping point after the first 19 patients completed the au-
tologous HSCT and allogeneic NST. These patients
were followed for TRM until 100 days after allogeneic
NST. Because no treatment-related deaths occurred in
the first 100 days in these 19 patients, the primary end-
point was achieved, and the study was subsequently re-
opened to accrual. During the accrual period, groups
from Seattle and Germany, with the same basic study
design, reported results demonstrating the feasibility,
toxicity, and efficacy of this concept [9,11]. Enrollment
to this study slowed precipitously, and the study was
terminated early because of slow accrual, likely related
to the publication of this approach by these other
investigators [9] rather than due to toxicity. Regard-
less, the present study does demonstrate the feasibility
and safety of performing a tandem autologous-
nonmyeloablative allogeneic HSCT whithin a cooper-
ative group.
In our study, 32 patients from 10 institutions were
initially enrolled. The dropout rate was 28%, consis-Table 4. Comparison of Tandem Transplantation Trials
Characteristic
Current
study
Rosinol
et al.15
Bruno
et al.12
Geo
et a
Number 32 25 58 13
Graft Sibling Sibling Sibling MU
Median age, years 52 52 55 4
Dropout, % 28 NA 28 N
Conditioning
Autologous Mel Mel Mel M
Allogeneic Flu/Cy Flu TBI Flu/
GVHD prophylaxis CSA CSA CSA CS
Pred MTX MMF MM
Responses, %
Post-autologous
CR 13 0 14
PR 61 NA 62 5
Post-allogeneic
CR 30 40 53 5
PR 48 NA 24 2
Median follow-up, months 42 62 38 3
EFS 50 months 61% at 5 years 43 months 51% at
OS 78% at 2 years NR NR 77% at
TRM (%) 9 16 10 2
% aGVHD, > II 17 32 43 6
% cGVHD L/E 30/27 66 32/32 -/7
NA, not available; MUD, matched unrelated donor; Mel, melphalan; Flu, flud
globulin; MMF, mycophenolate mofetil; MTX, methotrexate; L/E, limited/exten
*Five failed previous autologous transplantation.tent with that from other reported tandem HSCT
studies (Table 4). In this study, we used a cyclophos-
phamide- and fludarabine-based preparative regimen,
whereas more recent NST trials have used a melpha-
lan-based regimen (eg, melphalan 1 fludarabine) or
low-dose TBI (eg, 200 cGy) (Table 4). For the 23
patients who completed both transplantations, the
cumulative CR rate increased from 9% after induction
to 30% after NST. The low CR rate after autologous
HSCT probably reflects the heterogeneity of the pa-
tient group included in the trial, which did not require
chemotherapy sensitivity for eligibility; however, the
overall response rate is comparable to that for previous
tandem HSCT trials, especially when considering that
30% of our patients had chemotherapy-resistant dis-
ease at the time of study enrollment (none of whom
achieved CR). Furthermore, the present study used
a GVHD prophylaxis regimen consisting of cortico-
steroids and CSA, resulting in a 70% incidence of
acute GVHD and a 57% incidence of chronic
GVHD. More recent studies have incorporated myco-
phenolate mofetil, tacrolimus, or antithymocyte
globulin, with no appreciably different rates of acute
and chronic GVHD. Thus, there is no absolute
‘‘standard’’ preparative regimen or GVHD prophy-
laxis at this time. Finally, our nonhematologic toxic-
ities also were comparable to those of other reported
studies, even though this study was designed at
a time when allogeneic NST was still considered
highly investigational.
The actuarial survival rate at 2 years was 78%. We
observed only a single graft failure. Whereas Brunorges
l.14
Garban
et al.10
Martino
et al.13
Maloney
et al.9
Kroger
et al.11
* 46 15 54 17
D Sibling Sibling Sibling MUD/sibling
4 54 51 50 51
A 29 21 4 NA
el Mel Mel Mel Mel
Cy Bu/Flu Flu/Cy TBI Mel/Flu
A ATG/CSA CSA CSA ATG/CSA
F MTX MTX MMF MTX
8 11 27 20 18
4 72 67 37 60
4 33 47 57 70
3 48 53 26 20
6 24 44 18 17
3 years 31.7 months 42% at 4 years 24 months 56% at 2 years
3 years 35 months 100% 78% at 20 months 74% at 2 years
3 11 0 17 18
7 24 13 38 38
5 7/36 40 18/46 7/33
arabine; Cy, cyclophosphamide; Pred, prednisone; ATG, antithymocyte
sive.
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the HSCT-NST arm, our TRM of 8.7% is the lowest
reported to date. This incidence is especially low consid-
ering that this approach was quite novel when first pro-
posed in 1998 and was conducted within a cooperative
group. These results are superior to those from previous
studies for NST for myeloma, as well a number of more
current trials (Table 4). The lower TRM was indepen-
dent of the incidence of acute and chronic GVHD ob-
served in this trial compared with other reports,
supporting the idea that allogeneic NST can be safely
conducted in the cooperative group setting.
With a median follow-up of 4.6 years, we observed
1 relapse among the 7 patients in CR. Of the 11 pa-
tients in PR, 8 relapsed, with a median time to relapse
of 2.8 years. Admittedly, it is unknown whether the pa-
tients who have relapsed may have had adverse cytoge-
netic features, because these data were not available.
Acute GVHD developed in 70% of patients; chronic
GVHD, in 57%. Unfortunately, the development of
GVHD did not correlate with a significant increase
in CR; combining the incidence of chronic GVHD ob-
served de novo or after DLI (ECOG E1A97), only
24% (4 of 17) of patients achieved CR. One other pa-
tient with CCR also developed chronic GVHD. The
median PFS and OS of these 5 patients did not differ
significantly from those of the other 12 patients who
developed chronic GVHD or from those of the entire
cohort of patients achieving CR.
Although GVHD is known to be associated with
GVM [19-21], we found no association between
chronic GVHD, whether de novo or after DLI, with
improved outcome. In contrast, other reports indicate
that chronic GVHD is associated with improved out-
comes [22,23]. For GVM to be durable, it must be
effective in the setting of minimal residual disease;
various studies have shown that NST performed late
in the course of disease can result in high response
rates, but these responses are not durable even in the
setting of chronic GVHD [5-7]. Furthermore, in our
study, none of the 5 patients with chemotherapy resis-
tant disease achieved CR. Thus, the strategy applied in
this study (myeloablative autologous HSCT, followed
by allogeneic NST) may be the only potentially useful
approach to providing long-term disease control, but it
should be performed early in the course of disease, at
the time of minimal disease. Incorporating novel ther-
apies, such as bortezomib and/or lenalidomide, in
more recent induction regimens has produced
response rates exceeding 70%, including CR or nCR
in the 20% to 30% range [24-26]. These patients are
ideal for proceeding to a tandem autologous NST-
regimen. In virtually every disease and setting, out-
comes decline when transplant is utilized late, rather
than early in the disease course.
With a median follow up of 4.6 years, the median
PFS was 3.6 years and the 2-year survival rate was78% for the 23 patients who completed both trans-
plantations. These rates are comparable to those re-
ported previously by groups from Seattle and
Germany (Table 4). Unfortunately, however, neither
of these studies nor the current report demonstrates
a plateau in PFS. In addition, the recent tandem
HSCT-NST trial conducted by an Italian group also
did not appear to have a plateau in survival curves. In
contrast, the Spanish PETHEMA study may show
a plateau in survival, but at the ‘‘cost’’ of higher rates
of TRM (16%) and chronic GVHD (66%) [15]. On
the positive side, our TRM of 8.7% is almost identical
to the 10% and 11% rates reported by Italian and
French studies, respectively [10,12], and lower than
the 16% to 18% reported by the Spanish, Seattle,
and German groups [9,11,15].
This trial as well as the others cited here have dem-
onstrated that the tandem HSCT-NST approach is
feasible, even in multi-institutional settings. In con-
templating future approaches, a few additional lessons
may be evident from the current and prior reports. The
approach to autologous transplant for myeloma, based
on a high dose melphalan backbone, is widely utilized.
In the near term future, new agents may be added to
the conditioning, but the melphalan backbone is likely
to remain. In contrast, approaches to NST are quite
heterogenous in both the preparative and immunosup-
pressive regimens. More importantly, while all NST
trials perform analyses of myeloma response, there is
much less consistency regarding the evaluation and re-
porting of post transplant chimerism. This is a key is-
sue as it relates to the effectiveness of the GVM
response. For example, Garben et al [10] reported
that 86% of patients in their trial achieved full donor
chimerism on day 60 but this decreased to 72% on
day 120, perhaps due to the use of ATG in the condi-
tioning regimen. Whether it dropped further over
time is unknown, but they reported that all patients
with persistent partial chimerism had progressive dis-
ease. Going forward, chimerism analyses from periph-
eral blood samples should be an obligate requirement
of NST trials. It is unlikely, after the intensity of an au-
tograft, that the gentler regimens used for NST that
are primarily designed for immunosuppression rather
than treatment of myeloma will, in and of themselves,
substantially ablate the disease further. Rather the goal
of NST should be achievement of complete donor chi-
merism in as high a percentage of patients as possible,
balanced against the need to retain a low TRM and low
rates of GVHD. Indeed, before more studies of tan-
dem autografts followed by NST are performed, it
may well be appropriate to first validate the NST reg-
imen that results in the desired levels of donor chime-
rism. In summary, our tandem transplantation trial
using autologous HSCT followed by allogeneic NST
conducted by the ECOG found an overall response
rate of 78%, with PFS and OS comparable to rates
90 Biol Blood Marrow Transplant 15:83-91, 2009D. H. Vesole et al.reported previously. Similar to other studies, chronic
GVHD was not associated with long-term disease
control. Thus, our current regimens can affect high re-
sponse rates, but without durable responses. If cure is
to be achieved, future trials should include patients
early in the disease course treated to maximal response
with novel therapies (eg, bortezomib and/or lenalido-
mide), to optimize pretransplantation response. Im-
mediately thereafter, an autologous transplant should
be performed for maximal tumor cytoreduction and
then allogeneic NST to eradicate residual disease. In-
deed, molecular remission can be achieved in a minor-
ity of patients after allogeneic NST. Patients with
molecular remission have improved PFS and OS
[27,28]. To improve eradication of minimal residual
disease, with the goal of achieving molecular remis-
sion, posttransplantation maintenance with novel
agents should be incorporated into the treatment reg-
imen. The use of these agents is based on the findings
that both proteasome inhibitors and immunomodula-
tory agents have shown activity for treatment of relapse
after NST [29,30]. Additionally, both of these agents
are in clinical trials regarding their efficacy in prevent-
ing or treating GVHD. Utilizing agents which may ad-
dress both any residual myeloma and the major
complication of allografting (GVHD) would be ideal.
With this type of approach, MM may be either truly
cured or ‘‘operationally’’ cured by returning to a state
of a low proliferative ‘‘benign’’ plasma cell dyscrasia,
akin to monoclonal gammopathy of undetermined
significance [31,32].ACKNOWLEDGMENTS
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